Amkay Products

What does Amkay Products do?

Amkay Products Ltd is a micro-cap company in the healthcare services industry, recently converted to a public limited company. It has a market cap of Rs 36 Cr, with key metrics including a P/E ratio of 11.00 and a return on equity of 33.40%.

Overview:<BR>Amkay Products Ltd operates in the healthcare services industry and is categorized as a micro-cap company.<BR><BR>History:<BR>Amkay Products Ltd was originally incorporated as "Amkay Products Private Limited" in 2007. It was later converted into a Public Limited Company, with the name changed to "Amkay Products Limited" on August 28, 2023. Revenue and profit data for the latest quarter are not available.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: N/A<BR>Market-cap value: Rs 36 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 11.00<BR>Industry P/E: 53<BR>Dividend Yield: 0.00%<BR>Debt-Equity: 0.54<BR>Return on Equity: 33.40%<BR>Price-to-Book: 3.60<BR><BR>Contact Details:<BR>Registrar Address: Not available.

Has Amkay Products declared dividend?

No Dividend History Available

Who are the peers of the Amkay Products?

Amkay Products' peers include Syngene Intl., Dr Lal Pathlabs, Poly Medicure, and others. While Poly Medicure leads with a 1-year return of 24.45%, Amkay Products has the lowest at -34.33%, indicating weaker performance compared to its peers.

Peers: The peers of Amkay Products are Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., Transgene Biotek, Samsrita Labs, Shree Pacetronix, and Adeshwar Meditex.<BR><BR>Quality Snapshot: Excellent management risk is observed at Dr Lal Pathlabs, while Good management risk is found at Syngene Intl., Poly Medicure, Indegene, Vijaya Diagnost., Amkay Products, and Shree Pacetronix, and the rest. Below Average management risk is noted at Adeshwar Meditex. Growth is rated as Excellent for none, Below Average for Dr Lal Pathlabs, Vijaya Diagnost., and Amkay Products, Average for Poly Medicure, Indegene, and the rest. Capital Structure is rated as Excellent for Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., and Shree Pacetronix, while Average is noted for Amkay Products, and Below Average for Adeshwar Meditex.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Poly Medicure at 24.45%, while Amkay Products has the lowest at -34.33%. Amkay Products' 1-year return is significantly lower than that of its peers. Additionally, the six-month return is negative for Syngene Intl., Poly Medicure, Vijaya Diagnost., Transgene Biotek, Shree Pacetronix, and Adeshwar Meditex.

What is the technical trend for Amkay Products?

As of May 29, 2025, Amkay Products is in a mildly bearish trend, indicated by daily moving averages and weekly Bollinger Bands, despite a mildly bullish weekly MACD and mixed signals from Dow Theory, with the stock underperforming relative to the Sensex.

As of 29 May 2025, the technical trend for Amkay Products has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by the daily moving averages indicating bearish momentum and the weekly Bollinger Bands also reflecting a bearish outlook. The weekly MACD shows a mildly bullish signal, but this is countered by the overall bearish sentiment from the daily indicators. The Dow Theory presents a mixed view with a mildly bearish weekly signal and a mildly bullish monthly signal. The stock's performance relative to the Sensex shows significant underperformance across multiple time frames, further supporting the bearish outlook.

Who are the top shareholders of the Amkay Products?

The top shareholder of Amkay Products is Kashyap Pravin Mody, holding 30.95%, with no pledged promoter holdings. The highest public shareholder is Rakesh Khanna at 1.11%, while individual investors collectively own 23.23% of the shares.

The top shareholders of Amkay Products primarily consist of the promoters, with Kashyap Pravin Mody holding the highest stake at 30.95%. There are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors (FIIs) holding shares. The highest public shareholder is Rakesh Khanna, who owns 1.11% of the shares. Additionally, individual investors collectively hold 23.23% of the company's shares.

How big is Amkay Products?

As of 24th July, Amkay Products Ltd has a market capitalization of 53.00 Cr, classified as a Micro Cap, with no valid financial data available for Net Sales or Net Profit for the latest four quarters. The balance sheet as of March 2024 shows Shareholder's Funds at 10.00 Cr and Total Assets at 17.74 Cr.

As of 24th July, <BR><BR>Market Cap: Amkay Products Ltd has a market capitalization of 53.00 Cr and is classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: There is no valid financial data available for Net Sales or Net Profit for the latest four quarters.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2024, with Shareholder's Funds valued at 10.00 Cr and Total Assets amounting to 17.74 Cr.

Is Amkay Products overvalued or undervalued?

As of September 15, 2025, Amkay Products is considered undervalued with a PE ratio of 13.61 and an EV to EBITDA of 11.27, making it more attractive compared to its peers, despite a year-to-date stock performance decline of -15.87% against the Sensex's 4.67% return.

As of 15 September 2025, the valuation grade for Amkay Products has moved from very expensive to very attractive, indicating a significant shift in its market perception. The company is currently assessed as undervalued. Key ratios supporting this conclusion include a PE ratio of 13.61, an EV to EBITDA of 11.27, and a ROE of 13.88%. <BR><BR>In comparison to its peers, Amkay Products stands out with a much lower PE ratio than Poly Medicure (56.25) and Blue Jet Health (34.63), both categorized as very expensive. This suggests that Amkay Products offers a more favorable valuation relative to its competitors. Despite a recent decline in stock performance compared to the Sensex, where it has underperformed with a year-to-date return of -15.87% against the Sensex's 4.67%, the underlying financial metrics indicate that the company is positioned well for potential growth.

When is the next results date for Amkay Products?

Amkay Products will announce its results on 12 November 2025.

Amkay Products will declare its results on 12 November 2025.

How has been the historical performance of Amkay Products?

Amkay Products has shown fluctuating performance over the past five years, with net sales increasing to 38.39 Cr in March 2025 from 31.07 Cr in March 2024, alongside improvements in profits and total assets, indicating a positive trend in recent years.

Answer:<BR>The historical performance of Amkay Products shows a fluctuating trend in net sales and profits over the past five years.<BR><BR>Breakdown:<BR>Amkay Products reported net sales of 38.39 Cr in March 2025, an increase from 31.07 Cr in March 2024 and 27.86 Cr in March 2023, although it was lower than the 40.70 Cr in March 2021. The total operating income followed a similar pattern, reaching 38.39 Cr in March 2025. The company's total expenditure, excluding depreciation, was 34.26 Cr in March 2025, up from 27.74 Cr in March 2024. Operating profit (PBDIT) increased to 5.45 Cr in March 2025 from 4.58 Cr in March 2024, while profit before tax rose to 4.30 Cr in March 2025 from 3.50 Cr in March 2024. Profit after tax also improved to 3.34 Cr in March 2025 compared to 2.63 Cr in March 2024. The company's total assets increased to 29.63 Cr in March 2025 from 17.74 Cr in March 2024, with total liabilities also rising to 29.63 Cr. The cash flow from financing activities showed a positive trend with a net cash inflow of 1.00 Cr in March 2025, indicating improved liquidity. Overall, while Amkay Products experienced some fluctuations, the recent years show a positive trajectory in sales and profitability.

Which are the latest news on Amkay Products?

Why is Amkay Products Ltd falling/rising?

As of 18-Jan, Amkay Products Ltd's stock price is rising to Rs 75.60, reflecting a 5.0% increase. This growth is driven by strong performance metrics, including a year-to-date rise of 22.43%, despite a decline in investor participation.

As of 18-Jan, Amkay Products Ltd's stock price is rising, currently at Rs 75.60, reflecting a change of 3.6 (5.0%) upward. This increase can be attributed to several factors. The stock has outperformed its sector by 6.49% today and has shown a consecutive gain over the last three days, accumulating a total return of 9.84% during this period. Additionally, despite opening with a loss of -4.99%, the stock managed to reach an intraday high of Rs 75.60, indicating strong recovery momentum.<BR><BR>Furthermore, the stock has demonstrated robust performance over various time frames, with a year-to-date increase of 22.43% compared to a decline of 1.94% in the benchmark Sensex. Over the past year, Amkay Products Ltd has risen by 37.45%, significantly outperforming the Sensex's gain of 8.47%. The stock is also trading above its moving averages across multiple time frames, suggesting a positive trend.<BR><BR>However, it is important to note that there has been a decline in investor participation, with delivery volume dropping by 58.33% against the 5-day average. Despite this, the overall performance metrics indicate a strong upward movement in the stock price.